IRIS
ASCIERTO, PAOLO ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.854
NA - Nord America 5.985
EU - Europa 2.271
Continente sconosciuto - Info sul continente non disponibili 725
SA - Sud America 347
AF - Africa 171
OC - Oceania 13
Totale 17.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.626
SG - Singapore 3.902
CN - Cina 1.116
VN - Vietnam 947
IT - Italia 656
JP - Giappone 633
FR - Francia 597
RU - Federazione Russa 382
BD - Bangladesh 331
HK - Hong Kong 322
BR - Brasile 232
IN - India 168
DE - Germania 166
CA - Canada 157
NL - Olanda 92
IQ - Iraq 88
GB - Regno Unito 87
MX - Messico 76
UA - Ucraina 60
PH - Filippine 47
FI - Finlandia 38
TH - Thailandia 36
AR - Argentina 33
ZA - Sudafrica 33
ES - Italia 30
KR - Corea 30
JM - Giamaica 29
ID - Indonesia 25
EG - Egitto 24
PK - Pakistan 24
CR - Costa Rica 20
EC - Ecuador 20
TR - Turchia 20
VE - Venezuela 20
PL - Polonia 19
GT - Guatemala 16
IE - Irlanda 16
JO - Giordania 16
MY - Malesia 16
SC - Seychelles 16
CH - Svizzera 14
KE - Kenya 14
SE - Svezia 14
NP - Nepal 12
TW - Taiwan 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
PY - Paraguay 11
SA - Arabia Saudita 11
AZ - Azerbaigian 10
CI - Costa d'Avorio 10
TN - Tunisia 10
CO - Colombia 9
DZ - Algeria 9
HN - Honduras 9
IL - Israele 9
BG - Bulgaria 8
MA - Marocco 8
AL - Albania 7
BO - Bolivia 7
CL - Cile 7
LB - Libano 7
NI - Nicaragua 7
AT - Austria 6
AU - Australia 6
BE - Belgio 6
DO - Repubblica Dominicana 6
EE - Estonia 6
LT - Lituania 6
NG - Nigeria 6
PR - Porto Rico 6
PT - Portogallo 6
RS - Serbia 6
AM - Armenia 5
BY - Bielorussia 5
CZ - Repubblica Ceca 5
PA - Panama 5
PS - Palestinian Territory 5
RO - Romania 5
TT - Trinidad e Tobago 5
CY - Cipro 4
HU - Ungheria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LV - Lettonia 4
PE - Perù 4
SY - Repubblica araba siriana 4
AD - Andorra 3
BH - Bahrain 3
BM - Bermuda 3
CW - ???statistics.table.value.countryCode.CW??? 3
ET - Etiopia 3
GA - Gabon 3
GR - Grecia 3
IR - Iran 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
Totale 16.556
Salva come PNG Salva come JPEG
Città #
San Jose 2.315
Singapore 1.486
Tokyo 618
Lauterbourg 523
Ashburn 515
Council Bluffs 441
Hong Kong 277
Ho Chi Minh City 267
Hanoi 213
New York 169
Beijing 162
Santa Clara 128
Los Angeles 119
Naples 111
Moscow 91
Hefei 74
Amsterdam 68
Dallas 66
Buffalo 63
Phoenix 62
Rome 54
Milan 49
Chicago 48
Chandler 47
Mexico City 46
Bar Harbor 44
Da Nang 40
Frisco 40
Toronto 40
Frankfurt am Main 39
Haiphong 38
Orem 38
Baghdad 37
São Paulo 37
Montreal 36
Memphis 34
Munich 32
Brooklyn 31
Jacksonville 25
The Dalles 24
Atlanta 22
Boston 22
Houston 22
Denver 21
Shanghai 21
Mumbai 20
Bangkok 18
Millbury 17
Johannesburg 16
Napoli 16
London 15
San José 15
Seattle 15
Amman 14
Cairo 14
Hải Dương 14
Kingston 14
Nairobi 14
Redondo Beach 14
San Francisco 14
Seoul 14
Warsaw 14
Woodbridge 14
Bari 13
Biên Hòa 13
Miami 13
Nanjing 13
Boardman 12
Des Moines 12
Newark 12
Princeton 12
Turin 12
Turku 12
Washington 12
Wilmington 12
Ann Arbor 11
Charlotte 11
Contursi Terme 11
Lahore 11
Las Vegas 11
Padua 11
Stockholm 11
Tashkent 11
Casandrino 10
Chennai 10
Detroit 10
Guatemala City 10
Nuremberg 10
Bologna 9
Florence 9
Genoa 9
Guangzhou 9
Kuala Lumpur 9
Palermo 9
Poplar 9
Quảng Ngãi 9
Toms River 9
Can Tho 8
Helsinki 8
New Delhi 8
Totale 9.318
Salva come PNG Salva come JPEG
Nome #
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up 263
Integrated genomics identifies MiR-181/TFAM pathway as a critical driver of drug resistance in melanoma 215
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 202
Innate Immune Cells in Melanoma: Implications for Immunotherapy 189
FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy 182
Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): A population-based study 165
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies 163
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology 153
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 147
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents 145
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 142
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab 134
Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma 123
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? 122
Clinical outcome prediction in COVID-19 patients by lymphocyte subsets analysis and monocytes’ iTNF-α expression 119
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic 112
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells 112
Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients 112
Nemo binding domain peptide could induce apoptosis in several melanoma cell lines 110
Severe protracted intestinal cryptosporidiosis associated with interferon g deficiency: pediatric case report. 107
NEMO-binding domain peptide induces apoptosis of human melanoma cells through inhibition of constitutive NF-kB activation 106
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps 102
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 95
HHV-8 prevalence, immunosuppression and Kaposi’s sarcoma in South Italy 89
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial 81
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 74
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. 69
Where Reflectance Confocal Microscopy Provides the Greatest Benefit for Diagnosing Skin Cancers: The Experience of the National Cancer Institute of Naples 64
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 64
Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma 64
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301 64
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma 59
Expression of the anti-apoptotic protein BAG3 in human melanomas. 57
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: A retropective study 57
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma 56
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma 56
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma 54
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial 54
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial 53
Antitumor Activity of BRAF Inhibitor and IFN alpha Combination in BRAF-Mutant Melanoma 52
Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 52
Prognostic value of serum VEGF in melanoma patients: a pilot study 51
When rarity meets thoracic cancers: a narrative review from ITMIG 2024 49
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma 49
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab 48
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial 47
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 47
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 47
Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment 46
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 46
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma 46
The role of BRAF V600 mutation in melanoma 45
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma 44
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial 44
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients 44
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study 42
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma 42
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma 42
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers 42
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 41
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) 41
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) 40
Defining the critical hurdles in cancer immunotherapy 40
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma 40
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial 40
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma 40
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 40
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: The Italian melanoma intergroup study 40
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP) 39
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 39
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy 39
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma 39
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations 39
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma 39
Development of muscle spasm during Vismodegib treatment and the effect of treatment interruptions: exploratory analyses from the STEVIE study 38
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy 38
Merkel-cell carcinoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 38
Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma 38
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis 38
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma 38
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts 38
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy 37
Emerging therapeutics for melanoma 37
CD73 as biomarker of advanced melanoma response to immunotherapy 37
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases 37
Combination therapy: the next opportunity and challenge of medicine 36
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery 36
Clinical and Histological Predictors of Advanced Basal Cell Carcinoma Recurrence After Complete Response to Hedgehog Pathway Inhibitors: A Retrospective Multicenter Observational Study 36
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients 36
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for 36
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort 36
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 35
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research 35
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies 35
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study 35
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma 35
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? 35
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study 35
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, 10.1038/s41591-023-02583-2) 35
Totale 6.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022222 0 4 0 1 1 3 4 15 131 9 16 38
2022/2023134 17 5 3 6 19 10 0 13 16 20 9 16
2023/2024149 10 20 24 17 6 11 2 17 2 2 23 15
2024/2025949 47 41 11 17 38 62 95 57 84 97 316 84
2025/202614.154 187 166 240 719 2.952 1.236 1.814 2.335 2.390 954 517 644
2026/20271.558 956 602 0 0 0 0 0 0 0 0 0 0
Totale 17.366